Clinical trials: Type 2 Diabetes (T2D)
Diabetes Mellitus, Type 2
Self Titration With Apidra to Reach Target Study (START)
Primary Objective: The primary objective of this study is to demonstrate non-inferiority of a patient-managed titration algorithm (including blood glucose monitoring) for the addition of a single dose of insulin glulisine at…
- Trial name
- NCT01013571
- Testing
- insulin glargine, Apidra (insulin glulisine)
- Where
- Canada
- Volunteers
- 493 people
- Sponsor
- Sanofi
Diabetes, Diabetes Mellitus, Type 2
Effects of Biphasic Insulin Aspart 70/30 vs. Exenatide in Type 2 Diabetes Patients Not Reaching Blood Glucose Targets on Metformin and a Sulfonylurea.
This trial is conducted in the United States of America (USA). The study will compare A1C reduction achieved in patients receiving biphasic insulin aspart 70/30 once or twice daily to patients receiving exenatide twice daily.
- Trial name
- NCT00313001
- Testing
- biphasic insulin aspart, exenatide
- Where
- United States
- Volunteers
- 373 people
- Sponsor
- Novo Nordisk A/S
Type2 Diabetes
Use of an Investigational Digital Therapeutic in Patients With Type 2 Diabetes
BT-001 is a software program intended to help patients with type 2 diabetes, under the guidance of their physician, improve glycemic control (i.e., levels of blood sugar).
- Trial name
- NCT05094401
- Testing
- BT-001
- Where
- United States
- Volunteers
- 76 people
- Sponsor
- Better Therapeutics
Diabetes Mellitus, Type 2
Add Glucokinase Activator to Target A1c
This trial is a multi-center, adaptive, randomized, double-blind, placebo- and active- controlled, parallel group, Phase 2 study in subjects with T2DM to evaluate the effect of TTP399 on HbA1c following administration for 6…
- Trial name
- AGATA (NCT02405260)
- Testing
- TTP399 400 mg, TTP399 800 mg, Sitagliptin 100 mg
- Where
- 20 sites in United States
- Volunteers
- 190 people
- Sponsor
- vTv Therapeutics
Type 2 Diabetes Mellitus
Comparison of the Efficacy and Safety of Insulin Glargine/Lixisenatide Fixed Ratio Combination to Insulin Glargine in Patients With Type 2 Diabetes Insufficiently Controlled on Basal Insulin
Primary Objective: To demonstrate the superiority of iGlarLixi (fixed ratio combination of insulin glargine and lixisenatide) to insulin glargine on glycemic control as assessed by glycated hemoglobin A1c (HbA1c) change in…
- Trial name
- Lixilan-L-CN (NCT03798080)
- Testing
- Insulin glargine/Lixisenatide (HOE901/AVE0010), Insulin glargine (HOE901), Metformin
- Where
- 45 sites in China
- Volunteers
- 426 people
- Sponsor
- Sanofi
Diabetes, Diabetes Mellitus, Type 2
Comparison of the Efficacy and Safety of Two Different Dose Adjustment Regimens for Insulin Degludec/Insulin Aspart in Subjects With Type 2 Diabetes Mellitus Previously Treated With Insulin Glargine
This trial is conducted in Africa, Asia, Europe and the United States of America (USA). The aim of the trial is to compare the efficacy and safety of two different titration algorithms for insulin degludec/insulin aspart…
- Trial name
- BOOST® (NCT01680341)
- Testing
- insulin degludec/insulin aspart
- Where
- 45 sites in United States, Algeria and 3 more
- Volunteers
- 272 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
Efficacy and Safety of Fixed Combination Therapy of Vildagliptin and Metformin (25/1000 mg Bid) in Patients With Type 2 Diabetes Inadequately Controlled With Prior Metformin Monotherapy (HbA1c 7.0-9.5%)
The present study is designed to evaluate the efficacy and safety of fixed combination therapy of vildagliptin and metformin (25/1000 mg bid) in patients with type 2 diabetes inadequately controlled with prior metformin…
- Trial name
- NCT00728351
- Testing
- vildagliptin + metformin, metformin
- Where
- 63 sites in United States, France and 3 more
- Volunteers
- 317 people
- Sponsor
- Novartis Pharmaceuticals
Obesity, Overweight
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes
The main purpose of this study is to see how orforglipron, compared with placebo, helps improve glycemic control in participants with obesity or with overweight and type 2 diabetes.
- Conditions
- Obesity, Overweight, Type 2 Diabetes
- Trial name
- NCT06972472
- Testing
- Orforglipron
- Where
- 80 sites in United States, Argentina and 5 more
- Volunteers
- 600 people
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes Mellitus
Evaluate Safety and Effectiveness of MBX-102 in Type 2 Diabetes Patients With Poor Glycemic Control on Metformin
To define the relative efficacy, safety and tolerability profiles of oral daily MBX-102 at daily doses of 400 and 600 mg vs. placebo and Actos® 30 mg (up-titrated to 45 mg after 8 weeks) when administered for up to 24 weeks in…
- Trial name
- NCT00814372
- Testing
- MBX-102, Actos, Metformin
- Where
- 26 sites in United States, India
- Volunteers
- 242 people
- Sponsor
- Gilead Sciences
Diabetes Mellitus, Type 2
Prescription Patterns, Resource Utilization & Costs - Add-on Therapy With Anti Dipeptidyl Peptidase-IVs vs Rosiglitazone
This retrospective database study analyzed resource utilization and costs associated with sitagliptin (STG) in comparison with rosiglitazone (RSG) added to metformin (MET) monotherapy among adults with a diagnosis of diabetes who…
- Trial name
- NCT01332370
- Testing
- Rosiglitazone + Metformin, Sitagliptin + Metformin
- Volunteers
- 5,391 people
- Sponsor
- GlaxoSmithKline
Type 2 Diabetes Mellitus
Comparative Study of HOE490 O (Glimepiride and Metformin) Compared With Placebo on Top of Glimepiride
Primary objective of this study is to confirm the efficacy of HOE490 O (glimepiride/metformin) compared with placebo on top of glimepiride in HbA1c change.
- Trial name
- NCT00924573
- Testing
- Metformin, Glimepiride (HOE490)
- Where
- Japan
- Volunteers
- 189 people
- Sponsor
- Sanofi
Diabetes Mellitus, Type 2
A Glycemic Control Evaluation of Glimepiride Versus Rimonabant on Top of Metformin in Type 2 Diabetes
The primary objective is to demonstrate, after 52 weeks of treatment, the non-inferiority of rimonabant 20 mg once daily (od) versus glimepiride od in reducing glycosylated haemoglobin (HbA1c) in overweight/obese patients with…
- Trial name
- ALLEGRO (NCT00449605)
- Testing
- Rimonabant, Glimepiride, Metformin
- Where
- 15 sites in United States, Chile and 12 more
- Volunteers
- 508 people
- Sponsor
- Sanofi
Type 2 Diabetes Mellitus
ECC5004 DDI Study With Atorvastatin, Rosuvastatin, Digoxin and Midazolam in Healthy Participants
This is a Phase 1, open-label, non-randomized, fixed sequence study designed to evaluate the effect of ECC5004 on single dose pharmacokinetics of Atorvastatin, Rosuvastatin, Digoxin and Midazolam in healthy participants.
- Trial name
- NCT06293742
- Testing
- ECC5004, Midazolam, Rosuvastatin
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Eccogene
Type 2 Diabetes
Assessment of Probiotics on Inflammation and Metabolism in Type 2 Diabetes.
This clinical study aims to explore the effects of probiotics on inflammatory and metabolic indicators in patients with type 2 diabetes.
- Trial name
- NCT06440486
- Testing
- Probiotics
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Wecare Probiotics Co., Ltd.
Type-2 Diabetes Mellitus
A U.S. Pilot Human Investigation of RadiofrEquency Vapor Ablation System to Evaluate Safety, TOleRability, and Effectiveness for Proximal Intestinal Mucosal Ablation in Patients With Type 2 Diabetes Mellitus (RESTORE-1 Study)
The purpose of this study is to assess the safety, tolerability and effectiveness of RF vapor ablation of the proximal intestinal mucosa.
- Trial name
- RESTORE-1 (NCT07355270)
- Testing
- RF Vapor Ablation
- Where
- 4 sites in United States
- Volunteers
- 20 people
- Sponsor
- Aqua Medical, Inc.
Diabetes Mellitus Type 2
A Study of DPP-IV Inhibitor in Patients With Type 2 Diabetes
This study will assess the efficacy, safety and tolerability of DPP-IV Inhibitor in patients with type 2 diabetes receiving a stable dose of metformin.
- Trial name
- NCT00111631
- Testing
- DPP-IV Inhibitor, Metformin
- Where
- 37 sites in United States, Australia and 4 more
- Volunteers
- 218 people
- Sponsor
- Hoffmann-La Roche
Type 2 Diabetes
Study of CRx-401 on Glucose Levels in Subjects With Type II Diabetes
This trial will assess the efficacy of CRx-401 in lowering FPG levels in patients taking metformin to treat their diabetes. In addition, this initial trial will evaluate insulin resistance (HOMA-IR index), HgbA1c levels, glycated…
- Trial name
- NCT00506298
- Testing
- bezafibrate + diflunisal
- Where
- 18 sites in Canada
- Volunteers
- 150 people
- Sponsor
- Zalicus
Type 2 Diabetes
A Study to Evaluate P-Glucose, Safety and Tolerability After Oral Single Dosing of AZD6370 in Type 2 Diabetic Patients
The purpose of this study is to assess the effect of AZD6370 on blood sugar and to study safety and tolerability in patients with type 2 diabetes.
- Trial name
- NCT00690287
- Testing
- AZD6370
- Where
- 3 sites in Sweden
- Volunteers
- 24 people
- Sponsor
- AstraZeneca
Type 2 Diabetes Mellitus
18-Week, Randomized, Double-blind, Placebo Controlled, Forced Titration Study of Patients With Type 2 Diabetes
Designed to evaluate dose response of force-titrated prandial administration of TI as compared to placebo (TP) in subjects with Type 2 diabetes who were suboptimally controlled
- Trial name
- NCT00511732
- Testing
- Technosphere Insulin
- Volunteers
- 227 people
- Sponsor
- Mannkind Corporation
Diabetes Mellitus, Type 2
A Study Comparing Subcutaneous Rapid Acting Insulin and One Formulation of Inhaled Insulin in Subjects With Type 2 Diabetes
The original protocol was a randomized, open-label, 3-way cross-over study with 9 scheduled visits. The visits comprised an initial screening visit, 3 treatment visits for the meal challenge followed by a 2-6-week blood-loss…
- Trial name
- NCT00570687
- Testing
- Technosphere Insulin
- Where
- Germany
- Volunteers
- 30 people
- Sponsor
- Mannkind Corporation
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.